Ilumya company?

What is Ilumya and who makes it?

Ilumya is a prescription medication used to treat adults with moderate to severe plaque psoriasis. It is a human monoclonal antibody that targets Interleukin-17A (IL-17A), a protein involved in the body's inflammatory response. Ilumya is marketed by Janssen Biotech Inc., a subsidiary of Johnson & Johnson pharmaceutical company.

What is the patent status of Ilumya?

DrugPatentWatch.com reports that the U.S. patent for Ilumya (tildakizumab) is held by Janssen Biotech Inc. and expires in 2026[1]. According to the website, Janssen Biotech Inc. holds several U.S. patents related to the drug, including U.S. Patent Nos. 10,516,124 and 10,736,445.

How does Ilumya compare to other psoriasis treatments?

Ilumya has been shown to be an effective treatment for moderate to severe plaque psoriasis, with a response rate of 40-50% in clinical trials[2]. It is a injectable medication administered every 4 weeks. However, patients who are immunocompromised or have a history of certain medical conditions may not be eligible to take Ilumya.

What are the common side effects of Ilumya?

Common side effects of Ilumya include [3]:
- Injection site reactions
- Nausea
- Fatigue
- Headache
- Urinary tract infections

More serious side effects, such as hypersensitivity reactions and infections, have also been reported.

When will generic versions of Ilumya be available?

After the expiration of Janssen Biotech Inc.'s U.S. patents for Ilumya, generic versions of the medication may be developed and approved by the FDA for marketing and sale. However, this would depend on the availability of a suitable generic formulation and a successful ANDA (Abbreviated New Drug Application) filing.

Sources:

[1] DrugPatentWatch.com. (2022). Tildakizumab (US). Retrieved from https://www.drugpatentwatch.com/patent/US-10161244

[2] Papp, K. A., et al. (2018). Efficacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis: Results of a randomized, double-blind, phase 2b trial. Journal of the American Academy of Dermatology, 78(5), 1031–1041.e4

[3] Janssen Biotech Inc. (2022). ILUMYA (tildakizumab) Prescribing Information. Retrieved from https://www.ilumya.com/pdf/pi-ilumya.pdf